TSHA vs. EDIT, CCCC, ADPT, VYGR, ITOS, LXEO, FATE, ALVO, ALLO, and REPL
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Editas Medicine (EDIT), C4 Therapeutics (CCCC), Adaptive Biotechnologies (ADPT), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Alvotech (ALVO), Allogene Therapeutics (ALLO), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.
Editas Medicine received 217 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 73.28% of users gave Taysha Gene Therapies an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.
In the previous week, Editas Medicine had 24 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 29 mentions for Editas Medicine and 5 mentions for Taysha Gene Therapies. Editas Medicine's average media sentiment score of 0.32 beat Taysha Gene Therapies' score of 0.01 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.
Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Taysha Gene Therapies has lower revenue, but higher earnings than Editas Medicine. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Editas Medicine presently has a consensus target price of $13.90, indicating a potential upside of 143.43%. Taysha Gene Therapies has a consensus target price of $6.88, indicating a potential upside of 186.46%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Editas Medicine.
Editas Medicine has a net margin of -239.36% compared to Editas Medicine's net margin of -722.06%. Editas Medicine's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.
Summary
Taysha Gene Therapies beats Editas Medicine on 11 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
